Analysts think CLRB stock price could increase by 608%
Aug 07, 2024, 6:26 AM
8.48%
What does CLRB do
Cellectar Biosciences, Inc., based in Florham Park, New Jersey, specializes in developing phospholipid drug conjugates (PDCs) for cancer treatment and imaging, with a product pipeline that includes iopofosine targeting multiple myeloma and pediatric cancers. Founded in 2005, the company employs 15 people and focuses on cancer-targeting treatments through its PDC delivery platform, pursuing development both independently and via collaborations.
6 analysts think CLRB stock price will increase by 607.97%. The current median analyst target is $13.77 compared to a current stock price of $1.95. The lowest analysts target is $7.07 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.